Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Two different radiation boost strategies reduce local failures in NSCLC
Key clinical point: Both of two radiation boost strategies improved local control of locally advanced NSCLC compared with that seen historically.
Major finding: The 1-year rate of freedom from local failure was 97% with a boost to the whole primary tumor and 91% with a boost only to the part of the tumor having high metabolic activity on FDG-PET.
Study details: A multicenter phase 2 randomized trial among 107 patients with inoperable stage II to III NSCLC and a primary tumor measuring ≥4 cm (PET-Boost trial).
Disclosures: The trial was sponsored by The Netherlands Cancer Institute. The presenter disclosed no conflicts of interest.
Citation:
Lalezari F et al. ESTRO 2020. Abstract 609.